DERM — Journey Medical Corporation

Summary of Journey Medical Corporation's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $17.6 million, a 21% increase from $14.9 million in Q3 2024.
• Gross Margin: 67.4%, down from 69.4% year-over-year, but showing improvement from 63.5% in Q1 and 67.1% in Q2 2025.
• Operating Expenses: SG&A expenses rose to $12.1 million, up 6% from $11.4 million in the prior year.
• Net Loss: GAAP net loss of $2.3 million ($0.09 per share), slightly improved from a loss of $2.4 million ($0.12 per share) in Q3 2024.
• EBITDA: Improved to a loss of $500,000 from a loss of $1 million in Q3 2024. Adjusted EBITDA was positive at $1.7 million compared to $300,000 in the previous year.

2. Strategic Updates and Business Highlights

• Amrozi Launch: Significant growth with Amrozi contributing $4.9 million in Q3, a 75% increase from Q2. Total prescriptions grew by 146% quarter-over-quarter.
• Market Access: Over 100 million of 187 million commercial lives have access to Amrozi, with contracts secured with two of three major GPOs.
• Physician Engagement: Increased unique prescribers for Amrozi to over 2,700, a 50% increase from the last quarter, indicating strong adoption.
• Clinical Feedback: Positive physician feedback on Amrozi's efficacy and safety, with strong initial refill rates.

3. Forward Guidance and Outlook

• Q4 Expectations: Anticipation of becoming sustainably EBITDA positive in Q4 2025. Continued revenue growth expected as Amrozi gains market traction.
• Long-term Projections: Amrozi is projected to achieve peak annual net sales of over $200 million in the U.S. and over $300 million globally.

4. Bad News, Challenges, or Points of Concern

• Generic Competition: Legacy products, particularly Accutane, faced a 16% year-over-year revenue decline due to generic competition, although recent trends suggest stabilization.
• Market Access Delays: While initial contracts are in place, downstream health plan formulary adoption can take up to three quarters, potentially delaying revenue realization.
• Gross Margin Decline: The decrease in gross margin compared to the previous year raises concerns about pricing pressures and product mix.

5. Notable Q&A Insights

• Co-Pay Assistance Program: Management expects reliance on the co-pay assistance program to decrease as reimbursement improves, with significant gains anticipated in 2026.
• Depth vs. Breadth of Prescribing: The focus will be on both expanding the number of prescribers and increasing the volume of prescriptions from existing prescribers, with expectations of improved refill rates.
• Accutane Outlook: Management indicated that while Accutane has stabilized, ongoing competition remains a risk, and pricing strategies will be closely monitored.
• Operational Efficiency: The company aims to leverage existing infrastructure to manage operating expenses effectively, maintaining consistent expense growth relative to revenue increases.

Overall, Journey Medical Corporation demonstrated strong performance in Q3 2025, driven by the successful launch of Amrozi, while facing challenges from competition and market access dynamics. The outlook remains positive with expectations for continued growth and improved profitability.